Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.68 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.66 |
| ▸ | STAT3 | P40763 | 2/20 | 0.60 |
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | PDE6D | O43924 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24474235 | 0.97 | HDAC3 (0.69) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| Formic Acid SCHEMBL29794445 | 0.96 | HDAC3 (0.65) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| SCHEMBL23959052 | 0.96 | HDAC3 (0.69) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| SCHEMBL23959186 | 0.96 | HDAC3 (0.69) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| Formic Acid SCHEMBL29794485 | 0.94 | HDAC3 (0.65) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| Formic Acid SCHEMBL29794414 | 0.93 | HDAC3 (0.65) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| SCHEMBL29794429 | 0.92 | CRBN (0.63) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| SCHEMBL29794459 | 0.92 | CRBN (0.65) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| SCHEMBL24474289 | 0.91 | CRBN (0.66) | HDAC3HDAC1HDAC2NCOR2CRBN | |
| Formic Acid SCHEMBL29794437 | 0.91 | CRBN (0.64) | HDAC3HDAC1HDAC2NCOR2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| WO-2021216828-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | HDAC3 2518/4885HDAC1 2235/4885HDAC2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.